2. Anti-infection JAK/STAT Signaling Stem Cell/Wnt Metabolic Enzyme/Protease Apoptosis
  3. Parasite STAT Phosphatase MDM-2/p53 Apoptosis
  4. Fluacrypyrim

Fluacrypyrim, a Miticide, is a STAT3 inhibitor. Fluacrypyrim significantly increases the protein tyrosine phosphatases(PTPs) activity. Fluacrypyrim inhibits the growth of leukemia cells by a predominant G1 arrest with significant decrease of the protein and mRNA levels of cyclin D1. Fluacrypyrim selectively inhibits STAT3 signaling, inducing growth arrest and apoptosis in STAT3-dependent cancer cells. Fluacrypyrim mitigates IR-induced hematopoietic system injury mainly by preventing apoptosis in the HSCs. Fluacrypyrim demonstrates significant analgesic and anti-inflammatory effects by inhibiting uterine smooth muscle contraction and inflammatory responses.

For research use only. We do not sell to patients.

Fluacrypyrim

Fluacrypyrim Chemical Structure

CAS No. : 229977-93-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Fluacrypyrim Related Antibodies

Top Publications Citing Use of Products

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Fluacrypyrim, a Miticide, is a STAT3 inhibitor. Fluacrypyrim significantly increases the protein tyrosine phosphatases(PTPs) activity. Fluacrypyrim inhibits the growth of leukemia cells by a predominant G1 arrest with significant decrease of the protein and mRNA levels of cyclin D1. Fluacrypyrim selectively inhibits STAT3 signaling, inducing growth arrest and apoptosis in STAT3-dependent cancer cells. Fluacrypyrim mitigates IR-induced hematopoietic system injury mainly by preventing apoptosis in the HSCs. Fluacrypyrim demonstrates significant analgesic and anti-inflammatory effects by inhibiting uterine smooth muscle contraction and inflammatory responses[1][2][3][4].

Cellular Effect
Cell Line Type Value Description References
A549 IC50
9.8 μM
Compound: Fluacrypyrim
Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay
[PMID: 23664877]
HL-60 IC50
6.9 μM
Compound: Fluacrypyrim
Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay
[PMID: 23664877]
In Vitro

Fluacrypyrim (FAPM) (3-12 h) reduces the apoptosis rate of BMNCs and its subsets (Lin⁻, Lin⁻c-Kit⁺, LK, and LSK cells) after the 6.5 Gy irradiation[1].

Fluacrypyrim (5 μM, 4-10 h) decreases cell apoptosis by regulating the p53-PUMA pathway in the BMNC cells[1].

Fluacrypyrim (0.1-12 μM, 0-72 h) shows a strong concentration-dependent and time-dependent inhibition of HL-60 cells growth, with an IC50 of 3.8 μM[2].

Fluacrypyrim (1.5-12 μM, 6-36 h) induces G1 arrest of HL-60 cells with downregulation of cyclin-D1[2].

Fluacrypyrim (0.75-12 μM, 6-36 h) significantly inhibits constitutive phosphotyrosine levels of STAT3 (tyr705) in HL-60 cells, an effect that can be reversed by sodium pervanadate treatment[2].

Fluacrypyrim (0.75-12 μM, 12 h) induces a dose-dependent increase of tyrosine phosphatase activity in HL-60 cells[2].

Fluacrypyrim (3-12 μM, 8-24 h) significantly inhibits STAT3-dependent luciferase activity in both IL-6-stimulated HepG-2 cells and c-Src-transfected NIH 3T3 cells[2].

Fluacrypyrim (0.75-12 μM, 24 h) suppresses constitutively active STAT3, thereby blocking cyclin D1 and c-Myc expression in HL-60 cells[2].

Fluacrypyrim (0.75-12 μM, 24 h) preferentially suppresses growth of cancer cells harboring constitutively active STAT3, with IC50 s of 3.8 μM (HL-60 cells), 6.0 μM (K562 cells), 8.2 μM (XG-7 cells) and 12.3 μM (Jurkat-T cells)[2].

Fluacrypyrim (6-24 μM, 24 h) induces caspase-dependent apoptosis in breast carcinoma cells (MDA-MB-231 cells) that harbor constitutively activated STAT3[2].

Fluacrypyrim (0.62-10 μM, 60 min) significantly inhibits uterine contractions induced by Dinoprost (PGF2α) (HY-12956), Oxytocin (HY-17571), acetylcholine (Ach) and KCl in a dose-dependent manner (pD2 values ranging from 5.72 to 5.92)[3].

Fluacrypyrim (2.5-10 μM) inhibits PGF2α-induced MLC20 phosphorylation in myometrial cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Fluacrypyrim Related Antibodies

Cell Cycle Analysis[2]

Cell Line: HL-60 cells and MDA-MB-231 cells
Concentration: 0, 0.75, 1.5, 3, 6, 12 μM
Incubation Time: 6, 12, 24, 36 h
Result: Induced G1 arrest in HL-60 cells and MDA-MB-231 cells(24 μM, 48 h)

Real Time qPCR[1]

Cell Line: BMNC cells
Concentration: 5 μM
Incubation Time: 10 h
Result: Downregulated the expression levels of Puma, Bax, and Noxa markedly.

Western Blot Analysis[1]

Cell Line: BMNC cells
Concentration: 5 μM
Incubation Time: 4 h
Result: Downregulated the expression level of protein of p-p53, p53, Puma, Bax, Noxa, and cleaved Caspase-3.

Western Blot Analysis[2]

Cell Line: HL-60, K562 and XG-7 cells
Concentration: 0, 0.75, 1.5, 3, 6, 12 μM
Incubation Time: 6, 12, 24, 36 h
Result: Decreased the level of pRb (ser807/881) in HL-60 cells (3, 6, 12 μM).
Reduced the expression of cyclin D3 and CDK4 slightly and significantly only in the higher concentrations in HL-60 cells (3, 6, 12 μM).
Decreased the cyclin D1 expression dose-dependently in HL-60 cells (3, 6, 12 μM).
Decreased the STAT3 tyr705 phosphorylation without affecting STAT3 ser727 phosphorylation and total STAT3 protein level in HL-60, K562 and XG-7 cells (0, 0.75, 1.5, 3, 6, 12 μM).
Reduced the expression of STAT5 only at the highest concentration and showed no alteration on STAT1 in HL-60 cells (0, 0.75, 1.5, 3, 6, 12 μM).
In Vivo

Fluacrypyrim (20-75 mg/kg, i.p., 3-48 h before irradiation, single dose) mitigates IR-induced hematopoietic system injury in the C57BL/6J (CD45.2) mice and B6.SJL/BoyJ (CD45.1) mice[1].

Fluacrypyrim (50-200 mg/kg, i.p., 1 h before acid injection, single dose) reduces Acetic acid (HY-Y0319)-induced writhing response in mice[3].

Fluacrypyrim (100-200 mg/kg, i.p., 1 h before PGF2α injection, single dose) reduces inflammatory activities and pain response on mouse and rat swelling models[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: The male C57BL/6J (CD45.2) mice and male B6.SJL/BoyJ (CD45.1) mice(6-8 weeks) were subjected to either a sublethal dose (6.5 Gy) or lethal dose (8.0, 8.5, 9.0 Gy) of total body irradiation (TBI) using a 60Co γ-ray source at a dose rate of approximately 62 cGy/min[1]
Dosage: 20, 50, 75 mg/kg
Administration: i.p. 3, 24, and 48 h before irradiation
Result: Ameliorated pancytopenia in the mice subjected to irradiation (20, 50, 75 mg/kg) (6.5 Gy).
Improved the survival rate of mice after lethal irradiation(50 mg/kg) (8.0 Gy, 8.5 Gy, 9.0 Gy).
Alleviated irradiation-induced injury to BM (6.5 Gy).
Accelerated the recovery of HSPCs after irradiation exposure (6.5 Gy).
Enhanced the self-renewal capacity of HSCs after irradiation (CD45.2: 6.5 Gy) (CD45.1: 9.0 Gy)
Animal Model: KM male and female mice (22-28 g)[3]
Dosage: 50, 100, 200 mg/kg
Administration: i.p., 1 h before acid injection
Result: Reduced acetic acid-induced writhing response in mice
Animal Model: KM male and female mice (22-28 g) and female Sprague Dawley (SD) rats (120-140 g)[3]
Dosage: 50, 100, 200 mg/kg
Administration: i.p., 1 h before PGF2α injection
Result: Reduced inflammatory activities on mouse and rat swelling models.
Reduced PGF2α-induced pain response.
Molecular Weight

426.39

Formula

C20H21F3N2O5
CAS No.
Appearance

Solid

SMILES

COC(/C(C1=C(C=CC=C1)COC2=NC(OC(C)C)=NC(C(F)(F)F)=C2)=C/OC)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (234.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3453 mL 11.7264 mL 23.4527 mL
5 mM 0.4691 mL 2.3453 mL 4.6905 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.86 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (5.86 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3453 mL 11.7264 mL 23.4527 mL 58.6318 mL
5 mM 0.4691 mL 2.3453 mL 4.6905 mL 11.7264 mL
10 mM 0.2345 mL 1.1726 mL 2.3453 mL 5.8632 mL
15 mM 0.1564 mL 0.7818 mL 1.5635 mL 3.9088 mL
20 mM 0.1173 mL 0.5863 mL 1.1726 mL 2.9316 mL
25 mM 0.0938 mL 0.4691 mL 0.9381 mL 2.3453 mL
30 mM 0.0782 mL 0.3909 mL 0.7818 mL 1.9544 mL
40 mM 0.0586 mL 0.2932 mL 0.5863 mL 1.4658 mL
50 mM 0.0469 mL 0.2345 mL 0.4691 mL 1.1726 mL
60 mM 0.0391 mL 0.1954 mL 0.3909 mL 0.9772 mL
80 mM 0.0293 mL 0.1466 mL 0.2932 mL 0.7329 mL
100 mM 0.0235 mL 0.1173 mL 0.2345 mL 0.5863 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Fluacrypyrim Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fluacrypyrim229977-93-9ParasiteSTATPhosphataseMDM-2/p53ApoptosisMitcideSTAT3ionizing radiationhematopoietic stem cellsapoptosisp53-PUMAMDA-MB-231Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Fluacrypyrim
Cat. No.:
HY-W414644
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.